VistaGen Therapeutics
VTGN
VTGN
46 hedge funds and large institutions have $90.1M invested in VistaGen Therapeutics in 2023 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 15 increasing their positions, 2 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
35% more funds holding
Funds holding: 34 → 46 (+12)
33.07% more ownership
Funds ownership: 32.09% → 65.16% (+33%)
Holders
46
Holding in Top 10
–
Calls
$5.29M
Puts
$571K
Top Buyers
| 1 | +$13.8M | |
| 2 | +$10.3M | |
| 3 | +$9.55M | |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$9.34M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.13M |
Top Sellers
| 1 | -$1.2M | |
| 2 | -$726K | |
| 3 | -$395K | |
| 4 |
MA
MYDA Advisors
Woodmere,
New York
|
-$262K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$246K |